Fig. 9.
DFSs of patients with nonadvanced disease; 116 patients received cyclosporine/methotrexate, 58.4% (◊) and 97 patients received tacrolimus/methotrexate, 54.5% (□); absolute difference = 3.9%, 95% CI = −17.3 to 9.5 (P = .55, Wilcoxon).
DFSs of patients with nonadvanced disease; 116 patients received cyclosporine/methotrexate, 58.4% (◊) and 97 patients received tacrolimus/methotrexate, 54.5% (□); absolute difference = 3.9%, 95% CI = −17.3 to 9.5 (P = .55, Wilcoxon).
